Skip to content
AnalystLens

Exelixis 8-K Report, Financial Results (Feb 11, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 11, 2025
Period End
February 11, 2025
Security
EXEL
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Material agreement8-K · Dec ’19Dec ’19
  3. Leadership change8-K · May ’22May ’22
  4. Leadership change8-K · May ’26May ’26

Summary

Summary of the 8-K filed February 11, 2025. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. (Nasdaq: EXEL) filed this Form 8-K under Item 2.02 to furnish its press release (Exhibit 99.1) reporting financial results for the fourth quarter and fiscal year ended January 3, 2025 (presented as December 31, 2024), along with a corporate update.

Total revenues were $566.8 milliona for the quarter and $2,168.7 million for the year, up from $479.7 million and $1,830.2 million in the prior-year periods. Net product revenues were $515.2 million for the quarter and $1,809.4 million for the year, driven by higher sales volume and average net selling price. GAAP net income was $139.9 million ($0.48 diluted EPS) for the quarter and $521.3 million ($1.76 diluted EPS) for the year, while non-GAAP diluted EPS was $0.55 for the quarter and $2.00 for the year.

The company maintained its 2025 guidance, which does not reflect any revenue from a potential U.S. approval of CABOMETYX in previously treated advanced neuroendocrine tumors. The FDA's PDUFA target action date for that sNDA is April 3, 2025. Guidance calls for total revenues of $2.15 billion to $2.25 billionb and net product revenues of $1.95 billion to $2.05 billion.

Management highlighted zanzalintinib pivotal milestones in the second half of 2025, including top-line STELLAR-303 and STELLAR-304 results, and a decision on advancing STELLAR-305, along with Merck-sponsored zanzalintinib and belzutifan renal cell carcinoma studies. Other items disclosed include $205.6 millionc of stock repurchases under the ongoing $500 million 2024-25 program at an average price of $33.62 per share as of fiscal year-end, and a Paragraph IV certification from MSN Pharmaceuticals against another cabozantinib Orange Book patent (expiring 2032), which Exelixis is evaluating. The District Court previously ruled in Exelixis' favor in the second ANDA litigation, with the MSN generic launch date not earlier than January 15, 2030, subject to appeal.

Key Highlights

  1. Total revenues were $566.8 million in Q4 2024 and $2,168.7 million for FY2024, versus $479.7 million and $1,830.2 million a year earlier.
  2. Net product revenues reached $515.2 million in Q4 2024 and $1,809.4 million for FY2024, driven by higher sales volume and average net selling price.
  3. Cabozantinib franchise U.S. net product revenues were $1,809.4 million for FY2024, with CABOMETYX at $1,798.2 million; global franchise net product revenues generated by Exelixis and partners exceeded $2.5 billion.
  4. GAAP diluted EPS was $0.48 for Q4 2024 and $1.76 for FY2024; non-GAAP diluted EPS was $0.55 and $2.00, respectively.
  5. 2025 guidance was maintained: total revenues of $2.15–$2.25 billion and net product revenues of $1.95–$2.05 billion, excluding any potential CABOMETYX neuroendocrine tumor approval (PDUFA date April 3, 2025).
  6. Zanzalintinib pivotal readouts for STELLAR-303 and STELLAR-304, and a decision on STELLAR-305, are expected in the second half of 2025, pending event rates.
  7. Repurchased $205.6 million of common stock under the ongoing $500 million 2024-25 program at an average price of $33.62 per share as of fiscal year-end 2024.

Frequently Asked Questions

  1. What was Exelixis' revenue performance in the fourth quarter and full year 2024?

    Total revenues were $566.8 million for the fourth quarter and $2,168.7 million for the year ended December 31, 2024, compared with $479.7 million and $1,830.2 million for the same periods in 2023. Net product revenues were $515.2 million and $1,809.4 million, respectively, reflecting higher sales volume and average net selling price.

  2. What is the company's 2025 financial guidance?

    Exelixis maintained its 2025 guidance: total revenues of $2.15 billion to $2.25 billion, net product revenues of $1.95 billion to $2.05 billion, R&D expenses of $925 million to $975 million, and SG&A expenses of $475 million to $525 million. The guidance does not include revenue from a potential U.S. approval of CABOMETYX in advanced neuroendocrine tumors.

  3. When is the next major regulatory catalyst for Exelixis?

    The FDA's Prescription Drug User Fee Act (PDUFA) target action date for the supplemental New Drug Application for CABOMETYX in previously treated advanced neuroendocrine tumors is April 3, 2025. The company stated it is launch-ready for this indication.

  4. What are the key pipeline milestones for 2025?

    Management expects top-line results from the phase 3 STELLAR-303 (colorectal cancer) and STELLAR-304 (non-clear cell renal cell carcinoma) trials, and a decision to advance to the phase 3 portion of STELLAR-305 (head and neck cancer), in the second half of 2025, pending event rates. The STELLAR-311 trial in neuroendocrine tumors is planned to start in the first half of 2025, and additional phase 1b/2 zanzalintinib data are expected in the first half.

  5. What intellectual property developments were disclosed?

    The U.S. District Court for the District of Delaware ruled in Exelixis' favor in the second cabozantinib ANDA litigation against MSN Pharmaceuticals, stating that any FDA approval and U.S. launch of MSN's product would not occur before January 15, 2030, subject to additional exclusivity. Both parties have appealed to the Federal Circuit. In February 2025, MSN submitted a Paragraph IV certification regarding another Exelixis patent (U.S. Patent No. 12,128,039, expiring in 2032), which the company is evaluating.